272 related articles for article (PubMed ID: 30625392)
1. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.
Tamari R; Rapaport F; Zhang N; McNamara C; Kuykendall A; Sallman DA; Komrokji R; Arruda A; Najfeld V; Sandy L; Medina J; Litvin R; Famulare CA; Patel MA; Maloy M; Castro-Malaspina H; Giralt SA; Weinberg RS; Mascarenhas JO; Mesa R; Rondelli D; Dueck AC; Levine RL; Gupta V; Hoffman R; Rampal RK
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1142-1151. PubMed ID: 30625392
[TBL] [Abstract][Full Text] [Related]
2. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
Ali H; Aldoss I; Yang D; Mokhtari S; Khaled S; Aribi A; Afkhami M; Al Malki MM; Cao T; Mei M; O'Donnell M; Salhotra A; Pullarkat V; Yang L; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pillai R; Snyder D
Blood Adv; 2019 Jan; 3(1):83-95. PubMed ID: 30622146
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
5. Targeted Sequencing Improves DIPSS-Plus Prognostic Scoring in Myelofibrosis Patients Undergoing Allogeneic Transplantation.
Stevens EA; Jenkins IC; Beppu LW; Zhang Q; Salit R; Loeb KR; Deeg HJ; Radich JP
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1371-1374. PubMed ID: 32194289
[TBL] [Abstract][Full Text] [Related]
6. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model.
Hernández-Boluda JC; Pereira A; Alvarez-Larran A; Martín AA; Benzaquen A; Aguirre L; Mora E; González P; Mora J; Dorado N; Sampol A; García-Gutiérrez V; López-Godino O; Fox ML; Reguera JL; Pérez-Encinas M; Pascual MJ; Xicoy B; Parody R; González-Pinedo L; Español I; Avendaño A; Correa JG; Vallejo C; Jurado M; García-Cadenas I; Osorio S; Durán MA; Sánchez-Guijo F; Cervantes F; Piñana JL
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2237-2244. PubMed ID: 32717433
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.
Samuelson Bannow BT; Salit RB; Storer BE; Stevens EA; Wu D; Yeung C; Fang M; Petersdorf EW; Linenberger ML; Woo J; Sorror ML; Doney K; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2018 Feb; 24(2):386-392. PubMed ID: 28970176
[TBL] [Abstract][Full Text] [Related]
8. Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis.
Cyriac S; Prem S; Salas MQ; Chen S; Al-Shaibani Z; Lam W; Law A; Gupta V; Michelis FV; Kim DDH; Lipton J; Kumar R; Mattsson J; Viswabandya A
Eur J Haematol; 2021 Nov; 107(5):517-528. PubMed ID: 34260760
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.
Mannina D; Gagelmann N; Badbaran A; Ditschkowski M; Bogdanov R; Robin M; Cassinat B; Heuser M; Shahswar R; Thol F; Beelen D; Kröger N
Eur J Haematol; 2019 Dec; 103(6):552-557. PubMed ID: 31446640
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.
Hernández-Boluda JC; Pereira A; Kröger N; Cornelissen JJ; Finke J; Beelen D; de Witte M; Wilson K; Platzbecker U; Sengeloev H; Blaise D; Einsele H; Sockel K; Krüger W; Lenhoff S; Salaroli A; Martin H; García-Gutiérrez V; Pavone V; Alvarez-Larrán A; Raya JM; Zinger N; Gras L; Hayden P; Czerw T; P McLornan D; Yakoub-Agha I
Am J Hematol; 2021 Oct; 96(10):1186-1194. PubMed ID: 34152630
[TBL] [Abstract][Full Text] [Related]
11. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.
Kröger N; Panagiota V; Badbaran A; Zabelina T; Triviai I; Araujo Cruz MM; Shahswar R; Ayuk F; Gehlhaar M; Wolschke C; Bollin R; Walter C; Dugas M; Wiehlmann L; Lehmann U; Koenecke C; Chaturvedi A; Alchalby H; Stadler M; Eder M; Christopeit M; Göhring G; Koenigsmann M; Schlegelberger B; Kreipe HH; Ganser A; Stocking C; Fehse B; Thol F; Heuser M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1095-1101. PubMed ID: 28389256
[TBL] [Abstract][Full Text] [Related]
12. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
Salit RB; Deeg HJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):649-658. PubMed ID: 29128551
[TBL] [Abstract][Full Text] [Related]
13. JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes.
Rafati M; Brown DW; Zhou W; Jones K; Luo W; St Martin A; Wang Y; He M; Spellman SR; Wang T; Deeg HJ; Gupta V; Lee SJ; Bolon YT; Chanock SJ; Machiela MJ; Saber W; Gadalla SM
Blood Adv; 2023 Dec; 7(24):7506-7515. PubMed ID: 38011490
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.
Gagelmann N; Ditschkowski M; Bogdanov R; Bredin S; Robin M; Cassinat B; Shahswar R; Thol F; Heuser M; Socié G; Beelen D; Triviai I; Badbaran A; Kröger N
Blood; 2019 May; 133(20):2233-2242. PubMed ID: 30760453
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
[TBL] [Abstract][Full Text] [Related]
16. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
McLornan D; Szydlo R; Koster L; Chalandon Y; Robin M; Wolschke C; Beelen D; Socié G; Bornhäuser M; Angelucci E; Niederwieser D; Gerbitz A; Finke J; Vitek A; Itälä-Remes M; Radujkovic A; Kanz L; Potter V; Chevallier P; Stelljes M; Petersen E; Robinson S; Poiré X; Klyuchnikov E; Hernández-Boluda JC; Czerw T; Hayden P; Kröger N; Yakoub-Agha I
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2167-2171. PubMed ID: 31284069
[TBL] [Abstract][Full Text] [Related]
17. Mutations and prognosis in primary myelofibrosis.
Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
[TBL] [Abstract][Full Text] [Related]
18. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
Horvat NP; Abdallah EF; Xie Z; Al Ali N; Yun S; Walker A; Padron E; Sallman D; Chan O; Lancet J; Komrokji R; Kuykendall AT
Ann Hematol; 2024 Jan; 103(1):117-123. PubMed ID: 38030891
[TBL] [Abstract][Full Text] [Related]
19. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.
Scott BL; Gooley TA; Sorror ML; Rezvani AR; Linenberger ML; Grim J; Sandmaier BM; Myerson D; Chauncey TR; Storb R; Buxhofer-Ausch V; Radich JP; Appelbaum FR; Deeg HJ
Blood; 2012 Mar; 119(11):2657-64. PubMed ID: 22234678
[TBL] [Abstract][Full Text] [Related]
20. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis.
Tamari R; McLornan DP; Ahn KW; Estrada-Merly N; Hernández-Boluda JC; Giralt S; Palmer J; Gale RP; DeFilipp Z; Marks DI; van der Poel M; Verdonck LF; Battiwalla M; Diaz MA; Gupta V; Ali H; Litzow MR; Lazarus HM; Gergis U; Bashey A; Liesveld J; Hashmi S; Pu JJ; Beitinjaneh A; Bredeson C; Rizzieri D; Savani BN; Abid MB; Ganguly S; Agrawal V; Ulrike Bacher V; Wirk B; Jain T; Cutler C; Aljurf M; Kindwall-Keller T; Kharfan-Dabaja MA; Hildebrandt GC; Pawarode A; Solh MM; Yared JA; Grunwald MR; Nathan S; Nishihori T; Seo S; Scott BL; Nakamura R; Oran B; Czerw T; Yakoub-Agha I; Saber W
Blood Adv; 2023 Aug; 7(15):3993-4002. PubMed ID: 37134306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
